Opendata, web and dolomites

miRCaP SIGNED

Innovative nanoparticle formulation for a miR-133 based treatment of cardiac hypertrophy

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 miRCaP project word cloud

Explore the words cloud of the miRCaP project. It provides you a very rough idea of what is the project "miRCaP" about.

diagnosis    relies    muscle    strategies    inflammatory    heart    drugs    cardiac    players    inversely    capitalist    preclinical    strategic    dysregulations    nanoparticle    structural    unexpected    133    regulate    formulation    line    levels    business    candidates    cell    intellectual    nanoparticles    identification    toxicity    mir133    additional    pathogenesis    individual    commercial    successful    post    roles    remarkable    genes    efficiency    remodeling    ca    specificity    calcium    contraction    multiple    patient    selectively    worldwide    ing    found    strategy    defects    phosphate    toxic    selective    attracted    bioresorbable    causes    genetic    govern    release    drug    efficient    germane    cap    proof    treatment    np    therapeutic    stress    population    etiologies    outcome    50    functionalize    diseases    cardiovascular    hypertrophy    ischemic    micrornas    mortality    mir    innovative    preventing    translation    venture    unveiled    paid    failing    generate    pathological    nps    microrna    cds       biocompatible   

Project "miRCaP" data sheet

The following table provides information about the project.

Coordinator
HUMANITAS MIRASOLE SPA 

Organization address
address: VIA MANZONI 56
city: ROZZANO (MI)
postcode: 20100
website: www.humanitas.it

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Italy [IT]
 Total cost 150˙000 €
 EC max contribution 150˙000 € (100%)
 Programme 1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC))
 Code Call ERC-2015-PoC
 Funding Scheme ERC-POC
 Starting year 2016
 Duration (year-month-day) from 2016-12-01   to  2018-05-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    HUMANITAS MIRASOLE SPA IT (ROZZANO (MI)) coordinator 150˙000.00

Map

 Project objective

Innovative nanoparticle formulation for a miR-133 based treatment of cardiac hypertrophy

Cardiovascular diseases (CDs) are growing problems worldwide, affecting as much as 1% of the population. The causes include ischemic, toxic, genetic, post-inflammatory and structural defects; often multiple etiologies are present within an individual patient germane to the contraction failing, resulting in a mortality of ca. 50% within 5 years from diagnosis. Unexpected roles have been unveiled for microRNAs, important key-players in such pathogenesis, able to regulate levels of genes that govern cell remodeling. In line with this, development of microRNA-based drugs aimed at preventing stress-induced dysregulations of microRNA levels has attracted remarkable attention as potential candidates for therapeutic applications. Particular attention is paid to the miR-133, a muscle-specific microRNA, which has been found inversely related to pathological cardiac hypertrophy. However, a key challenge of microRNA-based drugs relies on delivery efficiency, toxicity and specificity. Here, we propose to generate innovative and effective therapeutic strategies based on the development of novel biocompatible and bioresorbable calcium phosphate nanoparticles (CaP-NP) for carrying miR-133 selectively to the heart. Our aim is to functionalize CaP-NPs for a selective delivery of the therapeutic miR133 to the pathological heart. The development of a novel approach based on CaP-NPs might be an efficient cardiac drug-delivery system for a specific release of miR-133. The successful outcome of this proposal will provide a relevant preclinical proof-of-concept necessary for 1) the development of additional Intellectual Properties, 2) the translation into a commercial strategy and business case, and 3) the identification of strategic partners and venture capitalist.

 Publications

year authors and title journal last update
List of publications.
2018 Irene Salamon, Gloria Saccani Jotti, Gianluigi Condorelli
The long noncoding RNA landscape in cardiovascular disease
published pages: 1, ISSN: 0268-4705, DOI: 10.1097/HCO.0000000000000507
Current Opinion in Cardiology 2019-06-13
2018 Serge Masson, Sandor Batkai, Julia Beermann, Christian Bär, Angelika Pfanne, Sabrina Thum, Michela Magnoli, Giovanna Balconi, Gian Luigi Nicolosi, Luigi Tavazzi, Roberto Latini, Thomas Thum
Circulating microRNA-132 levels improve risk prediction for heart failure hospitalization in patients with chronic heart failure
published pages: 78-85, ISSN: 1388-9842, DOI: 10.1002/ejhf.961
European Journal of Heart Failure 20/1 2019-06-13
2017 Roberto Papait, Simone Serio, Christina Pagiatakis, Francesca Rusconi, Pierluigi Carullo, Marta Mazzola, Nicolò Salvarani, Michele Miragoli, Gianluigi Condorelli
Histone Methyltransferase G9a Is Required for Cardiomyocyte Homeostasis and Hypertrophy
published pages: 1233-1246, ISSN: 0009-7322, DOI: 10.1161/CIRCULATIONAHA.117.028561
Circulation 136/13 2019-06-13
2017 Veronica Larcher, Paolo Kunderfranco, Marco Vacchiano, Pierluigi Carullo, Marco Erreni, Irene Salamon, Federico Simone Colombo, Enrico Lugli, Marta Mazzola, Achille Anselmo, Gianluigi Condorelli
An autofluorescence-based method for the isolation of highly purified ventricular cardiomyocytes
published pages: 409-416, ISSN: 0008-6363, DOI: 10.1093/cvr/cvx239
Cardiovascular Research 114/3 2019-06-13
2018 Leonardo Elia, Paolo Kunderfranco, Pierluigi Carullo, Marco Vacchiano, Floriana Maria Farina, Ignacio Fernando Hall, Stefano Mantero, Cristina Panico, Roberto Papait, Gianluigi Condorelli, Manuela Quintavalle
UHRF1 epigenetically orchestrates smooth muscle cell plasticity in arterial disease
published pages: 2473-2486, ISSN: 0021-9738, DOI: 10.1172/JCI96121
Journal of Clinical Investigation 128/6 2019-06-13

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "MIRCAP" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "MIRCAP" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.1.)

CITISENSE (2019)

Evolving communication systems in response to altered sensory environments

Read More  

iNANOVAC4CANCER (2019)

BIOHYBRID AND BIODEGRADABLE NANOVACCINES FOR CANCER IMMUNOTHERAPY

Read More  

Mu-MASS (2019)

Muonium Laser Spectroscopy

Read More